SOURCE: MicroMed Cardiovascular, Inc.

February 13, 2007 13:15 ET

MicroMed and NASA Come Together to Lend a Helping Heart on Valentine's Day

HOUSTON, TX -- (MARKET WIRE) -- February 13, 2007 -- MicroMed Cardiovascular, Inc. (OTCBB: MMCV) is a proud sponsor of The Methodist Hospital Left Ventricular Assist Device Program in Houston, Texas.

MicroMed Cardiovascular, Inc. and NASA Astronaut Scott Parazynski (M.D.) will join hearts February 14, 2007, with The Methodist Transplant Center, Houston, Texas, to celebrate a day of recovery and healing for patients who have benefited from ventricular assist devices and honor them for their bravery on their road to recovery.

The ventricular assist device (VAD) is a mechanical pump that helps the heart pump blood when it is too weak to do so due to congestive heart failure. The pump is implanted alongside the heart during surgery. The Methodist Hospital determines what VAD to use based on the patient's body size and specific medical needs. The goal for the patient is to live with the VAD long enough to receive a heart transplant. Some patients are not able to be transplanted and live permanently with the VAD. A few patients will be able to have their VAD explanted at some point in the future; if, their heart function returns to a reasonable level.

About MicroMed Cardiovascular, Inc.

The DeBakey VAD® is a small ventricular assist device which was jointly developed by the famed heart surgeon Dr. Michael E. DeBakey, Dr. George Noon, and the National Aeronautics and Space Administration (NASA). The DeBakey VAD® is a unique implantable axial flow device designed to provide long term, high quality of life for patients who suffer from congestive heart failure. It is the only device that provides accurate, real-time flow measurement improving clinicians' patient care. It is CE-Mark approved in Europe, undergoing a Bridge to Transplant clinical study in the U.S. and is the only FDA approved pediatric ventricular assist device.

For more information please visit our website at

This news release contains certain forward-looking statements pertaining to future anticipated projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this news release that are not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These statements by their nature are estimates of future results only and involve substantial risks and uncertainties. Actual results may differ materially from those indicated by these forward-looking statements as a result of various factors including, but not limited to, risks related to: our ability to obtain additional funding to support our business activities; the early-stage market for ventricular assist products and services; an expected dramatic rise in expenses; rapid growth and change in our business; as well as those risks more fully discussed in the Company's reports filed from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing its views as of any subsequent date. We do not undertake any obligation to update any forward-looking statements to reflect events or circumstances after the date of this release.

The MicroMed DeBakey VAD® is an investigational device and is limited by federal law for investigational use in the United States.

Contact Information

  • Media Contact:
    MicroMed Cardiovascular, Inc.
    Allison K. Wehner
    Corporate Communications
    Email Contact